Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Does vitamin D reduce blood pressure and left ventricular (LV) mass in resistant hypertensive patients with vitamin D insufficiency?
ISRCTN ISRCTN63688695
ClinicalTrials.gov identifier
Public title Does vitamin D reduce blood pressure and left ventricular (LV) mass in resistant hypertensive patients with vitamin D insufficiency?
Scientific title Does vitamin D reduce blood pressure and left ventricular (LV) mass in resistant hypertensive patients with vitamin D insufficiency? A double blind, placebo controlled, parallel group randomised trial.
Acronym N/A
Serial number at source Res08/A115
Study hypothesis Vitamin D insufficiency is common and low vitamin D levels are associated with higher blood pressure. Pilot data and previous studies suggest that vitamin D has anti-hypertensive effects, which may be mediated by pathways different from other anti-hypertensives. Vitamin D has not previously been studied as an anti-hypertensive in patients with resistant hypertension - a group for whom new approaches are urgently needed as they remain at high risk of cardiovascular events despite modern anti-hypertensive therapy.

Hypothesis:
That vitamin D supplementation in patients with resistant hypertension and insufficient vitamin D levels will lead to clinically important reductions in blood pressure.

Please note that as of 16/02/2009 this record was updated to include amended trial dates; the initial trial dates at the time of registration were:
Initial anticipated start date: 01/08/2008
Initial anticipated end date: 31/07/2010
Lay summary
Ethics approval Added 16/02/2009: Ethics Board of Fife, Forth Valley and Tayside Research Ethics Service gave approval in December 2008
Study design Double blind, placebo controlled, parallel group randomised trial
Countries of recruitment United Kingdom
Disease/condition/study domain Hypertension
Participants - inclusion criteria 1. Aged greater than 18 years, either sex
2. Serum 25-hydroxy vitamin D less than 75 nmol/L
3. Office blood pressure (BP) greater than 140/90 mmHg despite three or more anti-hypertensives
Participants - exclusion criteria 1. Hypertension known to be due to a correctable underlying medical or surgical cause
2. Estimated glomerular filtration rate less than 40 ml/min (by four variable Modification of Diet in Renal Disease [MDRD] equations)
3. Liver function tests (alanine aminotransferase [ALT], bilirubin, alkaline phosphatase) greater than 3 x normal
4. Corrected calcium greater than 2.60 mmol/L or less than 2.15 mmol/L
5. Known metastatic malignancy or sarcoidosis
6. Clinical diagnosis of osteomalacia
7. History of renal calculi
8. Diagnosis of heart failure with left ventricular systolic dysfunction
9. Atrial fibrillation
10. Already taking vitamin D supplements. Consumption of fish oils will not be a contra-indication to enrolment.
11. Unable to give written informed consent
12. Pregnant or of childbearing age and not taking reliable contraception
Anticipated start date 01/10/2008
Anticipated end date 31/10/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 74
Interventions 100,000 units of oral vitamin D3 every two months or placebo.

Total treatment duration: 4 months
Total follow up: 6 months
Primary outcome measure(s) Change in office BP, measured at 0, 2, 4 and 6 months.
Secondary outcome measure(s) Change in LV mass index (measured by cardiac magnetic resonance imaging [MRI]), measured at 0 and 6 months.
Sources of funding Chest Heart and Stroke Scotland (UK) (ref: Res08/A115)
Trial website
Publications
Contact name Prof  Allan  Struthers
  Address Dept of Clinical Pharmacology
Ninewells Hospital
  City/town Dundee
  Zip/Postcode DD1 9SY
  Country United Kingdom
  Email a.d.struthers@dundee.ac.uk
Sponsor University of Dundee (UK)
  Address Research and Innovation Services
11 Perth Road
  City/town Dundee
  Zip/Postcode DD1 4HN
  Country United Kingdom
  Email j.z.houston@dundee.ac.uk
  Sponsor website: http://www.dundee.ac.uk/
Date applied 28/03/2008
Last edited 16/02/2009
Date ISRCTN assigned 21/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central